1-6 of 6
Daniel Sullivan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Free
Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z. Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T. Hogan, Austin Doyle, Christina M. Annunziata, Martha Wellons, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1067–1075.
https://doi.org/10.1158/1078-0432.CCR-15-1076
Published: 29 February 2016
View articletitled, A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Free
Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View articletitled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

Free
Pamela Munster, Douglas Marchion, Elona Bicaku, Mira Lacevic, Jongphil Kim, Barbara Centeno, Adil Daud, Anthony Neuger, Susan Minton, Daniel Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2488–2496.
https://doi.org/10.1158/1078-0432.CCR-08-1930
Published: 01 April 2009
View articletitled, Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Open the PDF for Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC in another window
Journal Articles

Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression

Free
Nills Diaz, Susan Minton, Charles Cox, Tammy Bowman, Tanya Gritsko, Roy Garcia, Ibrahim Eweis, Marek Wloch, Sandy Livingston, Ed Seijo, Alan Cantor, Ji-Hyun Lee, Craig A. Beam, Daniel Sullivan, Richard Jove, Carlos A. Muro-Cacho
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 20–28.
https://doi.org/10.1158/1078-0432.CCR-04-1749
Published: 05 January 2006
View articletitled, Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression
Open the PDF for Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression in another window
Journal Articles

Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells

Free
Tanya Gritsko, Ann Williams, James Turkson, Satoshi Kaneko, Tammy Bowman, Mei Huang, Sangkil Nam, Ibrahim Eweis, Nils Diaz, Daniel Sullivan, Sean Yoder, Steve Enkemann, Steven Eschrich, Ji-Hyun Lee, Craig A. Beam, Jin Cheng, Susan Minton, Carlos A. Muro-Cacho, Richard Jove
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 11–19.
https://doi.org/10.1158/1078-0432.CCR-04-1752
Published: 05 January 2006
View articletitled, Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells
Open the PDF for Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells in another window
Journal Articles

Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study

Free
Adil Daud, Nikola Valkov, Barbara Centeno, Jennifer Derderian, Patricia Sullivan, Pamela Munster, Patricia Urbas, Ronald C. DeConti, Elmer Berghorn, Zhenmei Liu, Frederick Hausheer, Daniel Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 3009–3016.
https://doi.org/10.1158/1078-0432.CCR-04-1722
Published: 18 April 2005
View articletitled, Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study
Open the PDF for Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study in another window